$中国生物制药(01_老虎社区_美港股上老虎

爱因斯坦沽
12-04

$中国生物制药(01177)$ 智通财经APP讯，中国生物制药(01177)发布公告，集团自主研发的创新药TQF3250胶囊“口服偏向型GLP-1受体激动剂”的临床试验申请已获得中国国家药品监督管理局(NMPA)和美国食品药品监督管理局(FDA)的批准，拟用于减重。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":507127312782336,"tweetId":"507127312782336","gmtCreate":1764841059539,"gmtModify":1764841062197,"author":{"id":4108557628164870,"idStr":"4108557628164870","authorId":4108557628164870,"authorIdStr":"4108557628164870","name":"爱因斯坦沽","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01177\">$中国生物制药(01177)$ </a> 智通财经APP讯，中国生物制药(01177)发布公告，集团自主研发的创新药TQF3250胶囊“口服偏向型GLP-1受体激动剂”的临床试验申请已获得中国国家药品监督管理局(NMPA)和美国食品药品监督管理局(FDA)的批准，拟用于减重。</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/01177\">$中国生物制药(01177)$ </a> 智通财经APP讯，中国生物制药(01177)发布公告，集团自主研发的创新药TQF3250胶囊“口服偏向型GLP-1受体激动剂”的临床试验申请已获得中国国家药品监督管理局(NMPA)和美国食品药品监督管理局(FDA)的批准，拟用于减重。</p></body></html>","text":"$中国生物制药(01177)$ 智通财经APP讯，中国生物制药(01177)发布公告，集团自主研发的创新药TQF3250胶囊“口服偏向型GLP-1受体激动剂”的临床试验申请已获得中国国家药品监督管理局(NMPA)和美国食品药品监督管理局(FDA)的批准，拟用于减重。","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/507127312782336","repostId":0,"isVote":1,"tweetType":1,"viewCount":361,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["01177","SBHMY"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":216,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}